



香港藥業

**HONG KONG PHARMACEUTICAL HOLDINGS LIMITED**

**香港藥業集團有限公司\***

*(incorporated in Bermuda with limited liability)*

**(Stock code: 182)**

**APPOINTMENT OF NEW DIRECTOR  
AND  
PROPOSED CHANGE OF  
COMPANY NAME**

The board of directors (the “Board”) of Hong Kong Pharmaceutical Holdings Limited (the “Company”) announces that Mr. Liu Shunxing has been appointed as an executive director and the chief executive officer of the Company with effect from 13 July 2007.

To reflect the business development of the Group, the Board proposes to change the name of the Company to “China WindPower Group Limited” and to adopt the Chinese name “中國風電集團有限公司” (for identification purposes only).

**APPOINTMENT OF NEW DIRECTOR**

The Board is pleased to announce that the Board has appointed Mr. Liu Shunxing as an executive director and the chief executive officer of the Company with effect from 13 July 2007.

Mr. Liu Shunxing (劉順興), aged 45, has a master degree of energy source economy management from the management college of Harbin Institute of Technology. Mr. Liu is a member of China Energy Research Institute and the deputy director of the China Special Interest Committee of Thermoelectricity. He once worked in National Development and Reform Commission and once was the vice-president of China Energy Conservation Investment Corporation for eight years. Mr. Liu is familiar with the business of wind power and has directly commanded and successfully implemented investment and construction of three wind power plants. He has rich experiences in development, investment, construction and operation of clean and renewable energy source projects. Mr. Liu is also a director of China Wind Power Holdings Limited (the “Wind Power”, together with its subsidiaries and associates, the “Wind Power Group”) and a director of certain members of the Wind Power Group. Pursuant to a sale and purchase agreement entered into between the Company and China Wind Power Investment Limited on 29 April 2007, the Company has conditionally agreed to acquire and China Wind Power Investment Limited has conditionally agreed to sell the entire issued share capital of Wind Power (the “Acquisition”) subject to the terms and conditions of the sale and purchase agreement, including but not limited to the shareholders’ approval for the Acquisition, the sale and purchase agreement and the transactions contemplated thereunder at the special general meeting of the Company to be held on 30 July 2007. Mr. Liu does not hold any shares in any members of the Wind Power Group or China Wind Power Investment Limited. Please refer to the announcement and circular of the Company dated 21 May 2007 and 13 July 2007 respectively for further details of the Acquisition.

Mr. Liu has not entered into any service contract with the Company in respect of his directorship in the Company and there is no fixed or proposed length of service. The Company did not have any written or verbal agreement with Mr. Liu in respect of his emoluments or director's fees (if any). Save as disclosed above, Mr. Liu is not entitled to any monthly basic salary from the Company, but may be entitled to director's fee and/or emoluments based on his performance and experience and prevailing market conditions as the Board may from time to time determine. Mr. Liu will be subject to retirement and re-election at the special general meeting of the Company to be held on 30 July 2007 and will be subject to the retirement and re-election requirements under the bye-laws of the Company and the Code on Corporate Governance Practices of the Listing Rules.

Save as disclosed above, Mr. Liu did not hold any directorship in other public listed company or any other position with the Company or any of its associated corporations in the past three years. Save as disclosed above, Mr. Liu does not have any relationship with any other directors, senior management or substantial or controlling shareholder of the Company. As at the date of this announcement, Mr. Liu himself had no interest or short position in shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance.

There is no information which is discloseable nor is/was Mr. Liu involved in any of the matters required to be disclosed pursuant to any of requirements under paragraphs 13.51(2)(h) to 13.51(2)(v) of the Listing Rule.

Save as disclosed above, the Board is not aware of any other matter that is considered necessary to be brought to the attention of holders of the securities of the Company regarding the appointment of Mr. Liu.

The Board takes this opportunity to extend its warmest to Mr. Liu on joining the Board.

## **PROPOSED CHANGE OF COMPANY NAME**

To better reflect the business development of the Group, the Board proposed to change the name of the Company to "China WindPower Group Limited" and to adopt the Chinese name "中國風電集團有限公司" for identification purposes only. The proposed change of name will be effective subject to the passing of a special resolution to be proposed in the special general meeting of the Company to be held on 6 August 2007 and the approval of the Registrar of Companies in Bermuda. Further announcement will be made should the change of name of the Company become effective. Please refer to the circular of the Company dated 13 July 2007 for details.

*As at the date of this announcement, the Board comprises Mr. Ko Chun Shun, Johnson, Mr. Tsoi Tong Hoo, Tony, Mr. Chan Kam Kwan, Jason, Mr. Wong Fan, Frank, Mr. Yeung Heung Yeung (who are executive Directors), Mr. Kelvin Edward Flynn (who is a non-executive Director), and Mr. Ho Tak Man, Billy, Mr. Yap Fat Suan and Dr. Wong Yau Kar, David (who are independent non-executive Directors).*

By order of the Board  
**HONG KONG PHARMACEUTICAL HOLDINGS LIMITED**  
**Ko Chun Shun, Johnson**  
*Chairman*

Hong Kong, 12 July 2007

\* *for identification purpose only*